BiotechTube
ATUM

ATUM

Newark, United States· Est.
atum.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

ATUM is a private, revenue-generating biotechnology services and platform company providing integrated solutions for biologics development. Its core offerings include rapid gene synthesis (DNA2GO), high-throughput protein expression systems (lightningHEK, discoCHO), and proprietary cell line development, supported by computational biology and AI-driven design tools. With over 20 years of operation, ATUM serves as a critical partner for biopharma companies, accelerating the journey from discovery to preclinical development through its fully integrated, Bay Area-based facilities.

Synthetic BiologyGenetics & Genomics

Technology Platform

Integrated platform combining computational gene design (AI/ML, codon optimization), high-throughput gene synthesis (DNA2GO), parallel protein expression systems (lightningHEK, discoCHO), and proprietary cell line development (miCHO).

Funding History

2
Total raised:$30M
Series B$20M
Series A$10M

Opportunities

The expanding global biologics market creates sustained demand for ATUM's foundational services.
Its integrated, one-stop-shop model can attract clients seeking to reduce vendor complexity and accelerate timelines.
Growth in complex modalities (bispecifics, ADCs, etc.) increases the value of its protein engineering and optimization expertise.

Risk Factors

ATUM operates in a highly competitive CRO and gene synthesis market against larger, well-capitalized players.
Its revenue is tied to biopharma R&D budgets, which are cyclical.
The company faces technology disruption risk from new synthetic biology methods and must continuously innovate to maintain its value proposition.

Competitive Landscape

ATUM competes with large, public gene synthesis and life science tools companies (e.g., Twist Bioscience, GenScript), as well as specialized biologics development CROs and CDMOs. Its differentiation lies in its integrated platform, focus on speed (DNA2GO, lightningHEK), proprietary cell lines, and collaborative service model, all housed in a single Bay Area location.

More companies in Synthetic Biology →More companies in United States →